ABSTRACT The purpose of these studies was to determine the effects of uric acid (UA) and inosine administration on xanthine oxidoreductase activity in broilers. In experiment one, 25 broilers were assigned to 5 treatment groups: control, AL (25 mg of allopurinol/kg of body mass), AR (AL for 2 wk followed by allopurinol withdrawal over wk 3), UAF (AL plus 6.25 g of UA sodium salt/kg of feed), and UAI (AL plus 120 mg of UA sodium salt injected daily). The UA administration had no effect on plasma concentration of UA (P > 0.05), and all allopurinol-treated birds had lower (P < 0.05) UA levels than controls. The UA concentrations were restored in both plasma and kidney of AR birds at wk 3, but liver UA concentrations remained lower. Whereas xanthine oxidoreductase (XOR) activity in the liver (LXOR) was reduced (P < 0.05) by allopurinol treatment, XOR activity in the kidney (KXOR) was not affected (P = 0.05). In experiment two, 3 groups of 5 birds each were fed 0 (control), 0.6 M inosine/kg of feed (INO), or INO plus 50 mg of allopurinol/kg of body mass (INOAL). The INOAL birds showed lower total LXOR activity, but KXOR activity was not affected. Both INO and INOAL birds had higher plasma and kidney UA concentrations than controls. The results suggest that regulation of UA production is tissue dependent.
INTRODUCTION
Xanthine oxidoreductase (XOR) catalyzes the terminal reactions in purine degradation to uric acid (UA), a potent antioxidant for birds and humans. Specifically, XOR catalyzes the formation of UA from hypoxanthine and xanthine. The XOR exists in 2 interconvertible forms: xanthine oxidase (XO) and xanthine dehydrogenase (XD). In mammals, XOR is predominantly found in the XD form, which can be converted to XO either irreversibly via proteolysis or reversibly by oxidation of the sulfhydryl residues (Hille and Massey, 1981) . In the avian, a low, but detectable activity of XO has been measured in the liver and kidney (Remy and Westerfeld, 1951; Nishino et al., 1989; Harrison, 2002; Carro et al., 2009) . Despite this discovery, the majority of previous research in birds has focused on the activity of XD.
Previous studies have investigated the effects of diet on chicken XD activity (Scholz and Featherson, 1968; Itoh et al., 1978) , developmental patterns of XD in the embryo and the posthatching period , and tissue XOR distribution in broilers (Carro et al., 2009 ), but to our knowledge little is known about the regulation of XOR activity in birds.
The XOR reaction products include UA and reactive oxygen species (ROS), specifically the generation of peroxide and superoxide radicals. Both radical types are implicated in exacerbating oxidative damage to various tissues (Galbusera et al., 2006) . In contrast, UA is a pronounced antioxidant in birds (Simoyi et al., 2002; Stinefelt et al., 2005) . In most mammals, uricase converts UA to allantoin before excretion. In birds, humans, reptiles, and some higher primates, uricase is absent and therefore UA concentrations in the plasma remain elevated. Increased UA production has been shown to reduce oxidative stress (Simoyi et al., 2002) , whereas a reduction in UA dramatically increases oxidative stress (Klandorf et al., 2001; Carro et al., 2010) .
Inhibition of the XOR enzyme results from feeding allopurinol or oxypurinol, as well as from feeding molybdenum-deficient diets that are high in tungsten (Harrison, 2002) . Allopurinol is used to treat gout and hyperuricemia in humans. In birds, allopurinol decreases plasma uric acid (PUA) levels (Klandorf et al., 2001; Simoyi et al., 2002; Carro et al., 2010) , but
The effects of allopurinol, uric acid, and inosine administration on xanthine oxidoreductase activity and uric acid concentrations in broilers information on its effects on XOR activity is scarce, and the effects may be tissue dependent (Woodward et al., 1972; Carro et al., 2010) . To better understand factors that regulate XOR activity, we attempted to raise PUA levels by either exogenous administration of UA or inosine administration to broilers treated with allopurinol. The hypothesis was that allopurinol would have a downregulating effect on UA production and XOR activity, as evidenced by reduced UA concentrations and XOR activity, whereas supplementation with UA would restore baseline UA concentrations in the plasma and tissues.
MATERIALS AND METHODS
All experimental protocols were approved by the West Virginia University Animal Care and Use Committee.
Experiment 1
The purpose of this study was to determine the effects of administering allopurinol in concert with UA supplementation on XOR activity and UA concentrations in broilers. Uric acid, to our knowledge, has not been directly administered to broilers to restore plasma and tissue concentrations in allopurinol-treated animals, which has the potential to alleviate oxidative burden by increasing antioxidant defense.
Broilers and Experimental Procedure. Forty Cobb × Cobb mixed sex broilers were obtained from a local hatchery (Pilgrims Pride, Moorefield, WV) and maintained under standard husbandry practices. At 7 wk of age, 25 birds were selected and divided into 5 homogeneous groups according to their body mass (BM) and PUA concentrations, so that all pen mean values were similar at the onset of the study. Each group was randomly assigned to 1 of 5 treatments: CON (control), AL (allopurinol), AR (allopurinol recovery), UAF (UA in the feed), and UAI (UA injectable). Five birds were randomly assigned to each treatment. Birds in the CON group were fed a commercial broiler diet free of antibiotic additives, and each of the other groups was fed the same diet supplemented with allopurinol at 25 mg per kg of BM. This dose was used in previous experiments (Carro et al., 2010) and was shown to decrease PUA levels in broilers. After 2 wk, birds in the AR group were transferred to a CON diet to investigate the recovery from allopurinol supplementation. Birds in the AL, UAF, and UAI groups were maintained on their respective treatments during wk 3. Group UAF received UA sodium salt (Sigma Chemical Co., St. Louis, MO) mixed in the diet at an initial concentration of 6.25 g per kg of feed to ascertain whether UA could be absorbed across the intestinal lining and thereby increase PUA concentrations. This dose was selected to supply 1 g of UA each day, with higher doses reported to depress chicken growth (Bare et al., 1964) . Group UAI was injected daily with 3 mL of a solution containing 40 mg of UA sodium salt per mL (120 mg of UA sodium salt per bird) into the subcutaneous scapular region. Due to the reduced solubility of UA sodium salt, it was not possible to use a more concentrated solution that could be injected. To determine if PUA was affected by sampling time after injection, blood was obtained at 1 and 6 h after injection for 1 d and PUA concentrations were immediately determined.
Broilers were weighed twice weekly and feed intake was monitored 3 times a week for the experimental period. Blood samples (1.5 mL) were obtained from the wing vein and placed into heparinized tubes immediately before the start of the experiment to establish baseline UA concentrations for each bird and weekly afterward for the duration of the study. Blood was centrifuged at 2,000 × g for 20 min, and the plasma was removed for immediate analysis of UA.
After 3 wk of treatment, birds were euthanized by cervical dislocation and samples from the liver and kidney were placed into sterile bags. Samples were immediately frozen in liquid nitrogen and, once in the laboratory, stored at −80°C until analyzed for XOR activity and UA content. Liver weight was recorded, but due to the relative difficulty in rapidly excising the kidneys, kidney weights were not taken. Crop content was sampled, and about 4 g was placed on ice and frozen at −4°C until analysis for UA content.
XO and XD Activities. Tissue preparation and enzyme activity determination have been described in detail by Carro et al. (2009) . Briefly, frozen tissue samples (0.5 g) were homogenized in 4 mL of ice-cold 0.1 M Tris buffer (pH = 7.8) using a Polytron PT 2100 (Kinematika AG, Littau, Switzerland) for 20 s at 19,000 rpm. The homogenate was centrifuged (14,000 × g, 4°C, 30 min) and 1 mL of the supernatant fraction was immediately chromatographed on Sephadex G-25 (PD-10 desalting columns; GE Healthcare, Piscataway, NJ) and equilibrated with 1.5 mL of 0.1 M Tris buffer (4°C). The eluates were stored on ice and assayed for XO and XD activities within 1 to 2 h after homogenizing the tissue.
The XO and XD activities were assayed by measuring the formation of UA when xanthine was incubated with the eluates. Each eluate was incubated with 100 μM xanthine in the presence of ambient oxygen (XO activity) or with 100 μM xanthine and 0.67 mM NAD + (XO + XD activity). The reaction mixture contained 200 μL of eluate and 2.8 mL of 0.1 M Tris buffer (pH = 7.8) with 100 μM xanthine. The tubes containing the reaction mixtures were incubated at 41°C for 30 min, and absorbance was measured at 294 nm in a Beckman Spectrophotometer DU 640 (Beckman Instruments, Fullerton, CA). The amount of UA produced was determined from the difference between the absorbance values at 30 and 0 min, as compared with external standards of known UA concentration. Blanks containing xanthine and xanthine plus NAD + were incubated along with the sample tubes to correct for nonenzymatic oxidation of xanthine. Each assay was performed in duplicate.
One unit of activity was defined as the production of 1 nmol of UA per min at 41°C and pH 7.8 using 100 μM xanthine as substrate in the presence (XO + XD activity) or absence of 0.67 mM NAD + (XO activity). The XD activity was calculated as the difference between total (XO + XD) and XO activity. Specific activities were expressed in terms of units per milligram of protein in the eluate. The protein content in the eluate was assessed by Bio-Rad Protein Assay (Bio-Rad Chemical Division, Hercules, CA) according to the method of Bradford (1976) using serum albumin as standard.
UA Analysis. The UA concentration in plasma was measured in the supernatant fraction by using a commercially available diagnostic kit (Sigma Diagnostic kit procedure 685, Sigma Diagnostics, St. Louis, MO). This method employs uricase to generate H 2 O 2 , which reacts with 4-aminoantipyrine and 2,4,6-tribromo-3-hydroxy benzoic acid in the presence of peroxidise to form a quinoneimine dye. The resulting change in absorbance at 520 nm is proportional to the UA concentration in the sample.
Concentration of UA in liver and kidney samples was measured using the technique described for PUA analysis using 40 μL of the supernatant fraction from the homogenization of tissues for XOR analysis. For measuring UA concentration in crop contents, 0.5 g of contents were weighed and homogenized in 2 mL of ice-cold 0.1 M Tris buffer (pH = 7.8) and centrifuged at 14,000 × g at 4°C for 30 min. Concentrations of UA were analyzed in 80 μL of the supernatant fraction by the method described previously.
Experiment 2
The purpose of this study was to determine the effects of inosine, which increases UA concentrations, and a combination of inosine and allopurinol on the XOR activity and UA concentrations in the liver and kidney of broilers.
Broilers and Experimental Procedure. Twenty Cobb × Cobb mixed sex chicks at 1 d of age were donated from Pilgrim's Pride Hatchery (Moorefield, WV) and fed a commercial starter diet until 3 wk of age before replacement onto a commercial grower diet. At 5 wk of age, 15 birds were selected and divided into 3 homogeneous groups according to their BM and PUA concentrations. Each group was randomly assigned to 1 of 3 treatments: CON (control), INO (inosine), and INOAL (inosine with allopurinol). Birds in the CON group were fed a commercial broiler diet free of antibiotic additives. Birds in the INO group were provided the CON diet supplemented with inosine at a rate of 0.6 M inosine per kg of feed. Birds in the INOAL group received the CON diet containing inosine and allopurinol at 50 mg per kg of BM. This dose of inosine had been previously shown to raise PUA levels in broilers (Simoyi et al., 2002) . Supplementation of allopurinol was doubled compared with that of experiment 1 to ensure a rapid decrease of PUA levels, as a short-time study was planned to analyze changes in XOR activity.
Broilers were weighed and feed intake was monitored every 2 d through the 1-wk experimental period. Plasma UA was analyzed before the onset of the study to establish baseline concentrations, and 3 and 6 d afterward. After 6 d of treatment, birds were killed by cervical fracture and liver and kidney samples were taken for analysis of XOR activity and UA concentrations following the procedures described in experiment 1.
XO and XD Activities, and UA Analysis. Analyses of XO and XD activities and UA concentrations were performed as described previously for experiment 1.
Statistical Analysis
In both studies, the effects of experimental treatments on BM, UA concentrations, and activities of XO and XD were analyzed using ANOVA with treatment as the main effect. In experiment 1, the sums of squares were further partitioned by orthogonal contrasts that analyze the differences due to treatments. The contrasts were distributed as follows: C1, CON vs. AR; C2, CON vs. AL; C3, CON vs. UAF and UAI; C4, AL vs. UAF and UAI.
In experiment 2, Tukey's multiple comparison test was used to assess differences among means. All analyses were conducted using the PROC GLM of SAS (SAS Institute Inc., 2002, Cary, NC) for both studies. Correlations between UA concentration in liver and kidney were determined by Pearson correlation analysis using the PROC CORR of SAS software. Significance was defined in both studies as P ≤ 0.05.
RESULTS

Experiment 1
Feed intake in all groups receiving allopurinol decreased over the experiment (results not shown). Feed intake was monitored 3 times a week and concentrations of allopurinol or UA in feed were recalculated to obtain the intended allopurinol and UA consumption (25 mg per kg of BM or 1 g of UA per bird). At the end of the experiment, mean values of daily feed intake were 397, 174, 126, 119, and 133 g per bird for CON, AR, AL, UAF, and UAI groups, respectively.
As shown in Table 1 , after 2 wk of treatment, CON birds showed higher BM than birds in the AR (P = 0.026), AL (P = 0.047), and UAF and UAI (P = 0.018) groups. No differences (P = 0.904) were observed between birds fed allopurinol only and birds receiving allopurinol plus UA (UAF and UAI). At wk 3, CON birds maintained a higher BM than birds receiving allopurinol (P = 0.019) and allopurinol plus UA (P = 0.10). However, birds allowed to recover from allopurinol (AR) had the greatest percentage increase in BM between wk 2 and 3 compared with birds maintained on allopurinol.
There were no differences (P > 0.950) between groups in PUA concentrations at d 0, but 2 wk after the addition of allopurinol, birds in the CON group had higher (P < 0.001) PUA levels than all the other groups (Table  1 ). No differences (P = 0.404) were observed between AL birds and birds receiving allopurinol plus UA (UAF and UAI). At wk 3, AL birds maintained reduced (P = 0.025) PUA levels compared with the controls, but there were no differences between controls and AR (P = 0.328) and UAF and UAI (P = 0.106) birds. The PUA concentrations in UAF and UAI birds did not differ (P = 0.282) from those in AL birds.
The effects of experimental treatments on XO and XD activities and UA concentrations in the liver are shown in Table 2 . Control birds had higher liver weights than birds treated with allopurinol (P = 0.001) or with allopurinol and UA (UAF and UAI; P = 0.005), and tended (P = 0.061) to have higher liver weights than AR birds. No differences (P = 0.354) were observed between AL-and UA-supplemented groups.
There were no differences (P = 0.207 to 0.716) between treatments in XO activity. Birds in the AR group tended to have lower XD (P = 0.084) and XO+XD (P = 0.085) activity. There were no differences (P = 0.640 to 0.995) between the controls and the rest of the experimental groups. Concentrations of UA in the liver of CON birds, expressed both in milligrams per gram of tissue and as total milligrams in the liver, were higher (P < 0.001) than those in the liver of the birds in the AR, AL, UAF, and UAI treatments. Administration of UA (UAF and UAI treatments) did not affect (P > 0.850) liver UA concentrations compared with AL birds. Table 3 shows the effects of experimental treatments on UA concentrations in the kidney and crop contents and on XO and XD activities in the kidney. There were no differences (P = 0.133) in kidney UA concentrations between CON birds and those in the AR treatment. However, CON birds had higher (P < 0.001) kidney UA concentrations than birds treated with allopurinol and with allopurinol and UA. In a paired t-test comparison of UA concentrations (n = 25), kidney UA concentrations were higher (P < 0.001) than those measured in the liver, but there was a positive linear relationship between UA concentrations in both tissues (r = 0.805; P < 0.001; Figure  1 ). There is also a positive correlation between PUA concentrations and liver UA concentrations (r = 0.699; P < 0.001; Figure 2 ) as well as PUA concentrations and kidney UA concentrations (r = 0.722; P < 0.001; Figure 2 ).
No differences (P = 0.503 to 0.795) among experimental groups in XO activity were detected in the kidney (Table 3) . However, AL birds had lower XD (P = 0.036) and XO+XD (P = 0.050) activities compared with controls, and there was a trend (P = 0.075) toward lower XD activity in UA-supplemented birds than in controls.
Uric acid was detected in the crop content of all birds. The highest level of UA was detected in the UAF group (Table 3) , concentrations being 62, 60, 50, and 122 times higher than those found in CON, AR, AL, and UAI groups, respectively. No XOR activity in either the XO or XD form was detected in plasma samples in any group (data not shown).
Experiment 2
Although there were no differences (P = 0.853) in initial BM between the experimental groups (Table 4) , after 1 wk of treatment BM of the CON birds was higher (P < 0.001) than that of the INO and INOAL birds. No differences (P > 0.05) were detected between INO and INOAL groups.
As shown in Table 4 , PUA concentrations were similar (P = 0.847) in all groups at the onset of the study. After 3 d of treatment, INO birds had higher (P < 0.001) PUA levels than controls and INOAL birds. The INOAL birds had significantly higher PUA levels than CON birds. After 6 d of treatment, PUA concentrations remained elevated (P < 0.001) in INO and INOAL birds compared with CON birds, but no difference (P > 0.05) between INO and INOAL groups was measured.
The effects of experimental treatments on XO and XD activities and UA concentrations in the liver and kidney are shown in Tables 5 and 6 , respectively. After 6 d of treatment, INOAL birds had lower (P = 0.001) liver weights than birds in CON and INO groups, but no difference (P > 0.05) was observed between CON and INO groups. No differences (P = 0.673 to 0.875) between treatments in XO, XD, or XO+XD activity at the end of the study were detected. Concentrations of UA in the liver of INOAL birds, expressed both in Table 3 . Experiment 1: Effects of experimental treatments on uric acid concentration in the kidney and crop and activities of xanthine oxidase (XO) and xanthine dehydrogenase (XD) in the kidney of broilers (n = 5) 1 milligrams per gram of tissue and as total milligrams in the liver, were lower (P < 0.001) than those in the liver of CON and INO birds, whereas there were no differences (P > 0.05) between INO and INOAL birds.
No differences (P = 0.510 to 0.573) in UA between any of the groups in enzyme activity of the kidney were detected (Table 6 ). However, activity of the enzyme in the kidney was significantly lower than that in the liver, consistent with the previous study. Kidney UA concentrations in CON birds were lower (P < 0.05) than those found in the INO treatment, but no difference (P > 0.05) was detected between CON and INOAL groups.
DISCUSSION
Experiment 1
In agreement with previous studies (Klandorf et al., 2001; Carro et al., 2010) , allopurinol had an adverse effect on the BM of the birds in this study. Allopurinol reduced BM gain of the birds, and after 3 wk of treatment, BM in AL, UAF, and UAI birds was only 67, 69, and 68% of that in controls, respectively. However, our results contrast with data from another study done by Lee and Fisher (1972) , who fed chicks allopurinol (750 mg/kg of feed) from hatch to 28 d and noted no adverse effects of allopurinol on BM of the birds. Interestingly, there was a rebound in BM in the AR group compared with birds retained on allopurinol. In fact, daily BM gain over wk 3 was similar in CON and AR groups (691 and 640 g/d, respectively), and values were higher than those observed for birds fed allopurinol (323, 394, and 392 g/d for AL, UAF, and UAI, respectively). In this respect, these results reveal a rapid recovery of birds after eliminating allopurinol from the feed.
Uric acid is known to be a powerful antioxidant in birds (Simoyi et al., 2002; Stinefelt et al., 2005) , and reduced PUA concentrations are associated with an increase in oxidative stress (Simoyi et al., 2002; Carro et al., 2010) . All birds fed allopurinol showed significantly lower PUA after 1 wk of treatment compared with CON birds. It has to be taken into account that in poultry UA is a metabolic product of nitrogen, and protein intake was lower in allopurinol-treated broilers as a consequence of decreased feed intake. The lower protein intake in allopurinol-treated birds could have contributed to their lower PUA levels. Moreover, PUA levels are a reflection of the balance between tissue synthesis and urinary excretion. An increase in urinary UA output could account for decreased PUA levels. Two experimental groups (UAF and UAI) were administered UA to determine if XOR activity could be manipulated by increasing PUA concentrations through the addition of UA. However, significant increases in PUA were not achieved in any of the groups by the end of 3 wk of treatments, and PUA concentrations remained lower than in CON birds through the experimental period. This suggests that UA was not absorbed across the intestinal barrier of the birds, even though UA concentrations measured in the crop contents of UAF birds were markedly higher compared with the other groups. These results agree with those of Bare et a-c For each variable, means within a column lacking a common superscript differ (P < 0.05). al. (1964), who reported that UA concentrations in the intestinal contents of birds fed a diet containing 2% UA was between 40 and 60 times higher than those in CON birds. Bare et al. (1964) demonstrated that UA was degraded by Aerobacter isolates, which would support the hypothesis that part of UA was destroyed by the action of intestinal bacteria and never entered the blood stream. In contrast, Swain (1901) summarized several studies in which it was shown that feeding UA to dogs and cats increased allantoin excretion in urine, thus indicating UA absorption across the intestinal barrier. The PUA concentrations in the UAI group at 1 and 6 h after UA injection were similar (P = 0.751; 2.31 and 2.45 mg/dL, respectively), which suggests that the UA dosage administered was insufficient to meet the metabolic requirements of the chickens and raise PUA levels, despite the use of a saturated solution of UA sodium salt. Avian kidneys contain organic anion transporters, such as MRP4 (Bataille et al., 2008) , MRP2, OAT1, and OAT3 (Dudas et al., 2005) that extract UA from the plasma where it is then secreted from the renal proximal tubule epithelium into the urine. It is possible that the lack of increase in PUA is due to the inability to saturate the renal secretory capacity. At the end of the experimental period, birds in the AR group had recovered PUA concentrations similar to that measured in the CON birds, which is consistent with the recovery observed in daily BM gain of this group at wk 3.
The liver and kidney have been documented as a source of XOR activity in avian species (Strittmatter, 1965; Harrison, 2002; Carro et al., 2010) . The most studied form of XOR is XD, which is the more readily available form in the tissues. Little attention has been paid to XO in birds, although it has been identified in several tissues including the liver, kidney, intestine, and pancreas of broilers (Remy and Westerfeld, 1951; Strittmatter, 1965; Carro et al., 2009 ). In our study, there were no significant differences either in liver XO or XD activity among the experimental groups when enzyme activity was expressed as units per gram of tissue. Similar results have been reported by Carro et al. (2010) , who observed no differences between liver XO or XD activity in broilers administered 25 mg of allopurinol per kg of BM for 2 wk and the activity in CON birds, although allopurinol-treated birds had lower plasma UA concentrations. In agreement with a previous study (Carro et al., 2010) , XD and XO+XD activity in the kidney was reduced in birds treated with allopurinol. These results would indicate a differential effect of allopurinol on XOR activity in liver and kidney.
Birds treated with allopurinol had reduced concentrations of UA in liver and kidney as compared with CON birds. This agrees with previous studies (Carro et al., 2010) showing that broilers receiving 25 mg of allopurinol per kg of BM for 2 wk had lower UA concentrations in the liver, kidney, pancreas, and intestine as compared with CON birds. Allopurinol caused a marked decrease in UA concentrations in the liver without any effect on XOR activity, which may be due to a reduced feedback repression of XOR by UA. The XD and XO+XD activity were also reduced in the liver of AR birds compared with controls (40.0 vs. 25.8, and 48.1 vs. 32 .5 units/mg of protein, respectively), possibly caused by the increased UA concentrations compared with those in allopurinol-treated birds. In contrast, allopurinol decreased both UA concentrations and XD activity in the kidney, which suggests a direct effect on XOR activity. It has to be taken into account that UA concentration in the kidney also reflects UA that has been secreted into the tubular fluid and a lower UA renal secretion would result in lower UA concentrations in the kidney. At the end of this study, liver UA concentrations in AR birds remained lower than in controls, which indicate that recovery from the administration of allopurinol on liver XOR activity is not immediate upon cessation of allopurinol administration but requires additional time to return to CON levels. In contrast, UA concentrations in plasma and kidney were similar to those in CON birds just 1 wk after ceasing the administration of allopurinol. These results support the view that regulating mechanisms of XOR production are tissue specific, as previously suggested (Stirpe and Della Corte, 1965; Woodward et al., 1972; Carro et al., 2010) .
Concentrations of UA were higher in the kidney than in the liver, as previously reported by Carro et al. (2010) . As shown in Figure 2 , PUA concentrations were significantly correlated with UA concentrations in the liver (r = 0.699; P < 0.001; n = 25) and the kidney (r = 0.722; P < 0.001; n = 25), which agrees with previous studies reporting that both liver and kidney are important sources of UA in avian species (Remy and Westerfeld, 1951; Strittmatter, 1965; Carro et al., 2010) . The lack of XOR activity in the plasma (data not reported) observed in our study confirms previous observations (Al-Khalidi and Chaglassian, 1965; Carro et al., 2009) 
in birds.
Experiment 2
In the second study, inosine, a precursor known to increase UA concentrations in birds (Simoyi et al., 2002) , was administered separately and in combination with allopurinol. To our knowledge, this is the first study to investigate the effect of combining allopurinol and inosine on XOR activity and UA concentrations. The administration of inosine did not affect BM of birds, but the INOAL birds showed a decreased final BM at the end of the study compared with CON and INO birds. This is in accordance with previous observations in birds fed the same allopurinol dose (Carro et al., 2010) .
As in previous studies (Della Corte and Stirpe, 1967; Simoyi et al., 2002 Simoyi et al., , 2003 , birds in the INO group had significantly higher PUA than controls after 3 and 6 d of treatment, with INOAL birds having intermediate PUA concentrations but higher than in controls. This suggests that allopurinol was unable to completely inhibit the XOR activity. Surprisingly, liver UA concentrations were not affected by the administration of inosine, despite the higher UA concentrations observed in plasma and kidney of INO birds compared with the controls (3.2 and 7.1 times higher, respectively). These results suggest a different regulating mechanism of UA production in liver and kidney. This is also supported by the lack of relationship between UA concentrations in the plasma and liver observed in this experiment (r = 0.226; P = 0.697; n = 15; results not shown), whereas there was a positive linear relationship between UA concentrations in the plasma and kidney (r = 0.648; P = 0.009; n = 15; results not shown) as observed in experiment 1. Alternatively, the high concentration of UA observed in kidney may be related to the increased urate deposit coming from circulation.
Although there were no differences in the XOR activity in the liver between groups, when total XO+XD activity in the liver was calculated, the INOAL birds showed significantly lower total enzyme activity, indicating that the allopurinol was inhibiting enzyme activity compared with CON birds, confirming the results observed in experiment 1. In accordance with that, the birds in the INOAL group exhibited significantly lower UA concentrations in the liver compared with CON and INO birds. As in experiment 1, this observation suggests a pronounced residual effect of allopurinol, regardless of the presence of inosine, which is converted into UA. The lack of differences in liver UA concentrations and XOR activity between CON and INO birds indicates that inosine had no effect on UA concentrations or enzyme activity in the liver.
In conclusion, these studies show that allopurinol had a residual toxic effect in the liver and kidney, as indicated by chronically depressed UA concentrations in both tissues. These low UA tissue concentrations are an indication of increased susceptibility to oxidative stress, due to the inverse relationship that UA has with oxidative stress. The results also indicate that mechanisms regulating UA production in liver and kidney may differ, which should be confirmed by future work involving PCR analysis of tissues to quantify the relative gene expression of XOR to further increase our understanding of the mechanisms and role that XOR has within the avian.
